Core Insights - Earth Science Tech, Inc. (ETST) has engaged Semple, Marchal & Cooper, LLP as its new independent PCAOB auditor, marking a strategic upgrade in its financial governance infrastructure [1][2] - The decision to hire Semple is driven by the increased complexity of ETST's consolidated accounting due to its rapid expansion in pharmacy compounding, telemedicine, and real estate [2][3] Company Overview - ETST is a diversified holding company focused on the health and wellness sector, operating a vertically integrated portfolio that includes compounding pharmacies, telemedicine platforms, and healthcare facilities [4] - The company owns RxCompoundStore.com and Mister Meds, which are licensed compounding pharmacies providing sterile and non-sterile medications across a growing network of U.S. states [4] - ETST also manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand for innovative kitchen products [5] Governance and Strategic Direction - The Board of Directors believes that as ETST matures from a developmental stage to a rapidly growing diversified holding company, its corporate governance framework must evolve accordingly [2][3] - Jeff P. H. Cazeau, Independent Director and Chairman of the Audit Committee, emphasized the importance of selecting Semple for their reputation and ability to address the company's increasingly complex financial structure [3]

Core Insights - American Well Corporation (AMWL) reported a revenue of $55.31 million for the quarter ended December 2025, reflecting a year-over-year decline of 22.1% [1] - The earnings per share (EPS) was -$1.43, an improvement from -$2.77 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $52.51 million by 5.32%, while the EPS also surpassed the consensus estimate of -$1.59 by 10.06% [1] Revenue Breakdown - Platform subscription revenue was $28.84 million, exceeding the two-analyst average estimate of $26.14 million, but still down 22% year-over-year [4] - Other revenue amounted to $2.76 million, falling short of the two-analyst average estimate of $3.92 million, representing a significant year-over-year decline of 43.4% [4] - Revenue from visits reached $23.71 million, surpassing the two-analyst average estimate of $22.38 million, but still down 18.7% compared to the previous year [4] Stock Performance - Over the past month, shares of American Well have returned -8.7%, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it may perform in line with the broader market in the near term [3]

Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming healthcare delivery through a consumer-first digital platform focused on personalized, at-home care, with nearly 2.5 million subscribers as of Q3 2025 [1][7] Company Developments - The company has launched new offerings in men's health, including a testosterone category and compounded therapies, as well as a menopause specialty for women, both featuring personalized treatment plans [2][7] - Hims & Hers introduced Labs, a whole-body diagnostic service that combines biomarker testing with doctor-developed action plans, moving towards a preventive healthcare model [3][7] Market Performance - Hims & Hers shares have decreased by 71.8% over the past year, underperforming the industry average decline of 40.2% [6] - The forward 12-month price-to-sales ratio for HIMS is 1.4X, significantly lower than the industry average of 3.5X and its three-year median of 2.6X, indicating potential undervaluation [8] Earnings Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 suggests a 77.8% improvement from 2024, with estimates ranging from a low of $0.39 to a high of $0.57 [9][10]

Core Viewpoint - Teladoc Health, once thriving during the COVID-19 pandemic, is now facing stagnant and declining revenue, leading to concerns about its long-term viability as a company [1][12]. Company Overview - Founded in 2002, Teladoc Health specializes in remote medical appointments and had a successful IPO in 2015, experiencing steady share price growth until the pandemic [2]. - The company's stock price surged 224% from approximately $81 per share in late 2019 to a peak of $263 per share in January 2021 [4]. Current Financial Performance - By the end of 2023, Teladoc's share price had plummeted to $21, representing a 92% decrease from its peak [5]. - As of the latest data, the stock trades around $5, with a market capitalization of $861 million [6][7]. - Revenue for 2023 was reported at $2.6 billion, which is projected to decline by 1% to $2.5 billion in 2024, with further decreases anticipated in subsequent quarters [10]. Competitive Landscape - Teladoc faces significant competition from other telemedicine providers and traditional in-person medical services, with 71% of patients preferring in-person visits according to the National Institutes of Health [8][9]. - The company has struggled to maintain its market position as telemedicine becomes less dominant post-pandemic [9]. Profitability Challenges - Teladoc has never achieved profitability, with a net profit margin of negative 21% during its peak in 2021, improving slightly to negative 8.8% but still indicating ongoing financial struggles [11]. - The company is characterized by a lack of growth and profitability, raising concerns about its future sustainability [12].

Core Viewpoint - Earth Science Tech, Inc. (ETST) is set to report its financial results for the three months ending December 31, 2025, on February 17, 2026, after market close [1] Company Overview - ETST is a diversified holding company focused on the health and wellness sector, operating through wholly-owned subsidiaries [3] - The company has a vertically integrated portfolio that includes licensed compounding pharmacies, telemedicine platforms, and targeted healthcare facilities [3] - Current operations include RxCompoundStore.com and Mister Meds, which provide sterile and non-sterile medications across a growing network of U.S. states [3] - Telemedicine platforms Peaks Curative and Doconsultation.com connect patients with healthcare providers for personalized care [3] Additional Business Segments - Beyond healthcare, ETST manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand for innovative kitchen products [4] - The company is committed to social responsibility through the Earth Science Foundation, a non-profit organization aimed at assisting patients with prescription costs [4]

Group 1 - Teladoc Health, Inc. (NYSE:TDOC) has faced significant stock losses, with one investor reporting a nearly 96% loss in their IRA investment [1] - Jim Cramer advised against holding Teladoc stock, suggesting there are better alternatives in the market [1] - Teladoc provides virtual medical care services, including chronic condition management, mental health support, and specialized therapy [3] Group 2 - There is a belief that certain AI stocks present greater upside potential and carry less downside risk compared to Teladoc [4] - The article hints at the potential of AI stocks benefiting from trends such as Trump-era tariffs and onshoring [4]

As filed with the Securities and Exchange Commission on January 30, 2026 Registration No. 333-290302 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LYTUS TECHNOLOGIES HOLDINGS PTV. LTD. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 7841 Not applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) ...

Core Insights - Hims & Hers Health (HIMS) is a dynamic stock that attracts attention based on current trends and sales figures, particularly in the context of GLP-1 sales [1] Company Overview - Hims is focused on identifying asymmetric investment opportunities where potential upside significantly outweighs downside risks, even amidst uncertain timing or paths [1] - The company is open to exploring both classic value ideas and growth or tech opportunities when the risk-reward ratio is favorable [1] - Hims aims to uncover businesses that are currently overlooked or out of favor in the market [1]

Core Insights - Telehealth services offer convenience and potential savings for both physicians and patients, yet companies like Teladoc Health and Doximity have struggled in recent years [1][2] Group 1: Telehealth Market Dynamics - Medicare's reimbursement for telehealth services is set to expire on January 31, limiting coverage to specific cases, which is expected to reduce demand for telehealth [5][8] - The early pandemic years saw increased accessibility to telemedicine, but the upcoming changes in Medicare policy may reverse some of these gains [4] Group 2: Company Performance Outlook - Teladoc is anticipated to experience continued weak performance in 2026, with slow revenue growth and ongoing profitability challenges, exacerbated by the Medicare changes [6][7] - Doximity, while less affected by Medicare changes due to its broader service offerings, still faces a dim outlook in the current market environment [8][10] - Teladoc's international expansion shows some promise, but the company faces significant challenges that may hinder its recovery [9]

Group 1: Sarepta Therapeutics - Sarepta Therapeutics' shares declined by over 80% last year due to safety concerns surrounding its key product, Elevidys, which targets Duchenne muscular dystrophy (DMD) [3][4] - The company had to include a boxed warning for potential liver injury and restrict access to Elevidys after two patients died from liver failure [4][6] - For 2025, Sarepta expects revenue of $1.86 billion, a decline from $1.9 billion in the previous year, indicating a drop in demand for its medicine [6] - Despite efforts to develop new medicines and potential clinical progress, these products are not expected to impact financial performance in the near term [6][7] - Concerns remain regarding the safety of Sarepta's pipeline products, which could further affect investor confidence [7] Group 2: Teladoc Health - Teladoc Health has faced slow to non-existent revenue growth and accumulated net losses in recent years [8] - Increased competition in the telemedicine space has undermined Teladoc's market share, particularly affecting its virtual therapy platform, BetterHelp, which has seen a decline in paying members [9][10] - The company is attempting to improve its situation by seeking broader insurance coverage for BetterHelp and expanding internationally, but challenges similar to those faced domestically are anticipated abroad [12][13] - Teladoc's market cap stands at $1.1 billion, with a current price of $6.16, reflecting ongoing struggles in the market [11][12]